Understanding why some patients with blood cancers don't respond to interferon-alpha treatment
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11087672
This study is looking at how a specific type of blood cancer stem cell, especially those with CALR mutations, reacts to a treatment called interferon-alpha, to help understand why some patients benefit from the therapy even if their tumors don't shrink, with the goal of finding better treatment options for people with blood cancers.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11087672 on ClinicalTrials.gov |
What this research studies
This research investigates how certain blood cancer stem cells, particularly those with CALR mutations, respond to interferon-alpha therapy. By analyzing blood samples from patients, the study aims to uncover the molecular mechanisms that lead to therapy resistance. Using advanced techniques, researchers will examine how interferon-alpha affects the differentiation of these stem cells, potentially revealing why some patients experience clinical benefits without a corresponding decrease in tumor burden. The findings could provide insights that help improve treatment strategies for patients with myeloproliferative neoplasms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with CALR mutations.
Not a fit: Patients without myeloproliferative neoplasms or those who do not have CALR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with myeloproliferative neoplasms, enhancing their response to interferon-alpha therapy.
How similar studies have performed: Other research has shown promising results in understanding therapy resistance in blood cancers, making this approach both relevant and potentially impactful.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAM, SEUNG HA — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: NAM, SEUNG HA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.